Fenofibrate Initial Dosing
For adults with normal renal function and hypertriglyceridemia, start fenofibrate at 54-160 mg once daily with meals, with the specific dose individualized based on triglyceride severity. 1
Dosing by Indication
For Severe Hypertriglyceridemia (Triglycerides ≥500 mg/dL)
- Initial dose: 54-160 mg once daily with meals 1
- This range allows for dose titration based on response
- Adjust dosing at 4-8 week intervals based on repeat lipid panels 1
- Maximum dose: 160 mg once daily 1
For Primary Hypercholesterolemia or Mixed Dyslipidemia
- Initial dose: 160 mg once daily with meals 1
- This represents the standard starting dose for cholesterol management
Critical Pre-Treatment Requirements
Before initiating fenofibrate, you must evaluate renal function with both serum creatinine and eGFR 2. This is a Class I recommendation with moderate evidence (Level B) 2.
Renal Function-Based Dosing Adjustments
- eGFR ≥60 mL/min/1.73 m²: Use standard dosing (54-160 mg daily) 2, 1
- eGFR 30-59 mL/min/1.73 m²: Do not exceed 54 mg daily 2
- eGFR <30 mL/min/1.73 m²: Fenofibrate is contraindicated 2, 1
The ACC/AHA guidelines emphasize that renal monitoring must occur within 3 months after initiation and every 6 months thereafter 2.
Important Clinical Context
Available Formulations
Multiple fenofibrate formulations exist with different dosing equivalencies 2, 3. The Canadian guidelines note available doses of 100 mg, 145 mg, 160 mg, and 200 mg depending on formulation 3. Always consult manufacturer prescribing information as bioavailability varies between formulations 2.
Administration Requirements
Fenofibrate must be taken with meals to optimize bioavailability 1. This is not optional—food significantly enhances absorption.
When to Use Fibrates
According to current guidelines, fibrates should be considered when:
- Triglycerides are ≥500 mg/dL to prevent pancreatitis 4
- Triglycerides remain 200-499 mg/dL after statin therapy with elevated cardiovascular risk 4
However, fenofibrate may only be considered with low- or moderate-intensity statins (not high-intensity) and only if benefits outweigh risks 2. This is a Class IIb recommendation (may be considered) with weak evidence 2.
Common Pitfalls to Avoid
Never combine gemfibrozil with statins—this combination significantly increases rhabdomyolysis risk 2. Fenofibrate is the only fibrate that may be cautiously combined with statins.
Do not start at maximum dose in elderly patients—dose selection should be based on renal function, which commonly declines with age 1.
Avoid in patients with gallbladder disease—fenofibrate is contraindicated in preexisting gallbladder disease 1.
Monitor response appropriately—if no adequate response after 2 months at maximum dose (160 mg daily), discontinue therapy 1.
Monitoring Schedule
- Lipid panel: 4-12 weeks after initiation, then every 3-12 months 2
- Renal function: Within 3 months of starting, then every 6 months 2
- Liver function: As clinically indicated 2
The evidence supporting fenofibrate's cardiovascular benefit is limited. The ACCORD-Lipid trial showed no significant reduction in major cardiovascular events when fenofibrate was added to statin therapy 1. Therefore, the primary indication remains severe hypertriglyceridemia for pancreatitis prevention rather than cardiovascular risk reduction.